Benjamin W Teh
Overview
Explore the profile of Benjamin W Teh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung H, Krishnasamy M, Joyce T, Dryden T, Whitechurch A, Baden P, et al.
Vaccine
. 2025 Feb;
50:126826.
PMID: 39893769
Background: People affected by haematological malignancies are at high risk of morbidity and mortality caused by vaccine-preventable infections. However, vaccination commencement and completion following anti-cancer treatment is sub-optimal for this...
2.
Hall V, Smibert O, Sullivan S, Lim C, Barr I, Peck H, et al.
N Engl J Med
. 2025 Jan;
392(3):306-308.
PMID: 39813653
No abstract available.
3.
Coussement J, Heath C, Roberts M, Lane R, Spelman T, Smibert O, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39692570
Background: Limited data exist regarding outcomes of cryptococcosis in patients without HIV with few studies having compared outcomes of Cryptococcus gattii, versus C. neoformans, infection. Methods: We conducted a retrospective...
4.
Liu A, Slavin M, Harrison S, Teh B
Leuk Lymphoma
. 2024 Nov;
66(3):420-432.
PMID: 39555596
New generation therapies such as bispecific antibodies (BsAb), chimeric antigen receptor T-cell therapy (CAR T) and antibody-drug conjugates (ADC) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, there...
5.
Reynolds G, Klimevski E, Saunders N, Teenakoon G, Harrison S, Dowling M, et al.
Br J Haematol
. 2024 Oct;
205(6):2498-2502.
PMID: 39462188
No abstract available.
6.
Kampouri E, Reynolds G, Teh B, Hill J
Curr Opin Infect Dis
. 2024 Oct;
37(6):526-535.
PMID: 39361275
Purpose Of Review: Infections are the leading cause of non-relapse mortality following chimeric antigen receptor (CAR)-T-cell therapy, with viral infections being frequent both in the early and late phases post-infusion....
7.
Teh B, Reynolds G, Mikulska M, Mueller N, Slavin M
Blood Adv
. 2024 Jul;
8(22):5925-5926.
PMID: 39058974
No abstract available.
8.
Reynolds G, Maclean M, Cliff E, Teh B, Thursky K, Slavin M, et al.
Blood Adv
. 2024 Apr;
8(13):3555-3559.
PMID: 38625983
No abstract available.
9.
Hall V, Nguyen T, Allen L, Rowntree L, Kedzierski L, Chua B, et al.
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad550.
PMID: 38023562
Background: In-depth immunogenicity studies of tixagevimab-cilgavimab (T-C) are lacking, including following breakthrough coronavirus disease 2019 (COVID-19) in vaccinated patients with hematologic malignancy (HM) receiving T-C as pre-exposure prophylaxis. Methods: We...
10.
Hall V, Saunders N, Klimevski E, Tennakoon G, Khot A, Harrison S, et al.
Open Forum Infect Dis
. 2023 Oct;
10(10):ofad497.
PMID: 37869409
In patients early post-autologous stem cell transplant, seroprotection rates were high for type B and tetanus toxoid (70%-90%) but lower for (30%-50%) including after revaccination. There were high rates of...